233 related articles for article (PubMed ID: 37434249)
1. Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis.
Chen X; Xing H; Xie X; Kou L; Li J; Li Y
Clin Epigenetics; 2023 Jul; 15(1):113. PubMed ID: 37434249
[TBL] [Abstract][Full Text] [Related]
2. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
[TBL] [Abstract][Full Text] [Related]
3. IDH Inhibitors in AML-Promise and Pitfalls.
McMurry H; Fletcher L; Traer E
Curr Hematol Malig Rep; 2021 Apr; 16(2):207-217. PubMed ID: 33939107
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.
Aiman W; Ali MA; Basit MA; Omar Z; Suleman M; Hassan M; Jamil T; Anwar MS; Shafique Z; Dhanesar G; Faisal MS; Akerman MJ; Maroules M; Anwer F
Leuk Res; 2023 Jun; 129():107077. PubMed ID: 37100025
[TBL] [Abstract][Full Text] [Related]
5. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
Cortes JE
Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
[TBL] [Abstract][Full Text] [Related]
6. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Fathi AT; DiNardo CD; Kline I; Kenvin L; Gupta I; Attar EC; Stein EM; de Botton S;
JAMA Oncol; 2018 Aug; 4(8):1106-1110. PubMed ID: 29346478
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
8. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
[TBL] [Abstract][Full Text] [Related]
9. Updates on DNA methylation modifiers in acute myeloid leukemia.
Contieri B; Duarte BKL; Lazarini M
Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
12. Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.
Becker JS; Fathi AT
Curr Cancer Drug Targets; 2020; 20(7):490-500. PubMed ID: 32329690
[TBL] [Abstract][Full Text] [Related]
13. Enasidenib in mutant
Stein EM; DiNardo CD; Pollyea DA; Fathi AT; Roboz GJ; Altman JK; Stone RM; DeAngelo DJ; Levine RL; Flinn IW; Kantarjian HM; Collins R; Patel MR; Frankel AE; Stein A; Sekeres MA; Swords RT; Medeiros BC; Willekens C; Vyas P; Tosolini A; Xu Q; Knight RD; Yen KE; Agresta S; de Botton S; Tallman MS
Blood; 2017 Aug; 130(6):722-731. PubMed ID: 28588020
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.
Liu X; Gong Y
Biomark Res; 2019; 7():22. PubMed ID: 31660152
[TBL] [Abstract][Full Text] [Related]
15. Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies.
Yao K; Liu H; Yu S; Zhu H; Pan J
Cancer Lett; 2022 May; 533():215603. PubMed ID: 35227786
[TBL] [Abstract][Full Text] [Related]
16. Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness.
Liu ACH; Cathelin S; Yang Y; Dai DL; Ayyathan DM; Hosseini M; Minden MD; Tierens A; Chan SM
Cancer Res; 2022 Dec; 82(23):4325-4339. PubMed ID: 36150062
[TBL] [Abstract][Full Text] [Related]
17. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Issa G; Furudate K; Tanaka T; Pierce S; Tang G; Patel KP; Medeiros J; Abbas HA; Haddad F; Hammond D; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Pemmaraju N; Konopleva M; Garcia-Manero G; Ravandi F; Kadia TM; Loghavi S; DiNardo CD
Am J Hematol; 2022 Nov; 97(11):1443-1452. PubMed ID: 36054614
[TBL] [Abstract][Full Text] [Related]
18. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.
Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK
Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730
[TBL] [Abstract][Full Text] [Related]
19. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
Duchmann M; Micol JB; Duployez N; Raffoux E; Thomas X; Marolleau JP; Braun T; Adès L; Chantepie S; Lemasle E; Berthon C; Malfuson JV; Pautas C; Lambert J; Boissel N; Celli-Lebras K; Caillot D; Turlure P; Vey N; Pigneux A; Recher C; Terré C; Gardin C; Itzykson R; Preudhomme C; Dombret H; de Botton S
Blood; 2021 May; 137(20):2827-2837. PubMed ID: 33881523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
